{"entity":{"id":"nct05089734","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","aka":["EVOKE-01"],"tldr":"A phase 3 trial of Sacituzumab govitecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.","summary":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT05089734 by Gilead Sciences, with 603 participants enrolled, started 2021-11-17 and due to reach its primary completion in 2023-11-29. Interventions recorded: Sacituzumab Govitecan-hziy (SG), Docetaxel. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05089734","url":"https://clinicaltrials.gov/study/NCT05089734"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["sacituzumab-govitecan","docetaxel"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05089734","phase":"3","setting":"Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy","sponsor":"Gilead Sciences","started":"2021-11-17","startedType":"actual","yearReported":2025,"enrolled":603,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Survival (OS)","primary":true,"unit":"months","arms":[{"name":"Sacituzumab Govitecan (SG)","n":299,"value":11.1,"note":"95% CI 9.4 to 12.3; Figures from the ClinicalTrials.gov results section (first posted 2025-01-14), not from a publication"},{"name":"Docetaxel","n":304,"value":9.8,"note":"95% CI 8.1 to 10.6"}],"hr":0.84,"ci":[0.68,1.04],"p":"0.0534","source":"https://clinicaltrials.gov/study/NCT05089734?tab=results"}]},"route":"/trials/nct05089734/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}